Eye (London, England) · 2025
Photobiomodulation-induced choriocapillaris perfusion enhancement and outer retinal remodelling in intermediate age-related macular degeneration: a promising therapeutic approach with short-term results.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Viggiano Pasquale, Boscia Giacomo, Clemente Arcangelo, Laterza Mariapia, Termite Alba Chiara, Pignataro Maria Grazia, Salvelli Antonio, Borrelli Enrico, Reibaldi Michele, Giannaccare Giuseppe, Alessio Giovanni, Boscia Francesco
Аннотация
PURPOSE: To evaluate the effects of photobiomodulation (PBM) on choriocapillaris (CC) perfusion and drusen volume in patients with intermediate age-related macular degeneration (AMD).
METHODS: In this retrospective pilot study, 30 patients receiving PBM therapy and 30 age-matched controls were analysed. Treatment consisted of 8 sessions over 4 weeks using the EYE-LIGHT® device. Best-corrected visual acuity (BCVA), low luminance visual acuity (LLVA), mean drusen volume (MDV), and CC flow deficit percentage (FD%) were evaluated at baseline and 2-month follow-up.
RESULTS: The PBM group showed significant improvements in BCVA (Δ +3.2 ± 1.4 letters, p = 0.042), reduction in drusen volume (Δ -0.003 ± 0.001 mm³, p = 0.028), and decrease in choriocapillaris FD% (Δ -3.1 ± 1.4%, p = 0.024), while no significant changes were observed in the control group. Changes in choriocapillaris FD% correlated with BCVA improvement (r = -0.54, p = 0.002) and drusen volume reduction (r = 0.35, p = 0.042).
CONCLUSIONS: PBM therapy induces significant choriocapillaris remodelling in intermediate AMD, associated with functional improvement and drusen volume reduction. These findings suggest a potential therapeutic role of PBM in modulating choroidal perfusion in AMD.
METHODS: In this retrospective pilot study, 30 patients receiving PBM therapy and 30 age-matched controls were analysed. Treatment consisted of 8 sessions over 4 weeks using the EYE-LIGHT® device. Best-corrected visual acuity (BCVA), low luminance visual acuity (LLVA), mean drusen volume (MDV), and CC flow deficit percentage (FD%) were evaluated at baseline and 2-month follow-up.
RESULTS: The PBM group showed significant improvements in BCVA (Δ +3.2 ± 1.4 letters, p = 0.042), reduction in drusen volume (Δ -0.003 ± 0.001 mm³, p = 0.028), and decrease in choriocapillaris FD% (Δ -3.1 ± 1.4%, p = 0.024), while no significant changes were observed in the control group. Changes in choriocapillaris FD% correlated with BCVA improvement (r = -0.54, p = 0.002) and drusen volume reduction (r = 0.35, p = 0.042).
CONCLUSIONS: PBM therapy induces significant choriocapillaris remodelling in intermediate AMD, associated with functional improvement and drusen volume reduction. These findings suggest a potential therapeutic role of PBM in modulating choroidal perfusion in AMD.